Skip to main content

Table 4 main predictors of major adverse cardiac events during follow-up identified with univariate analysis

From: Outcomes and prognostic factors of patients treated for in-stent restenosis: a retrospective single-center experience

  % of MACEs p value
Clinical characteristics   
 Hypertension 58% versus 23.2% 0.049
 LDL-cholesterol > 1.4 mmol/l 38.7 versus 18.9% 0.02
 Absence of high-dose statins therapy* 17.9% versus 5.48% 0.03
Angiographic ISR characteristics   
 Early ISR (< 6 months) 18.1% versus 6.4% 0.042
 ISR of the proximal LAD 14.6% versus 8.9% 0.032
 Diffuse ISR 31% versus 10.3 0.05
 ISR occurring on a BMS 32.7% versus 20.6% 0.03
 Coronary status: triple or double vessel disease 17.8% versus 4.8% 0.016
Technical aspects of the initial angioplasty   
 Two or more stents per lesion 41.5% versus 19.1% 0.045
 Absence of post-dilatation 25.8% versus 3.4% 0.037
ISR treatment strategy   
 Medical treatment only 18.8% versus 8.1% 0.046
  1. BMS bare-metal stent, CABG coronary artery bypass graft surgery, DEB drug-eluting balloon, DES drug-eluting stent, ISR in-stent restenosis, LAD left anterior descending artery, MACE major adverse cardiac events, vs versus
  2. *Atorvastatin less than 80 mg once daily or Rosuvastatin less than 20 mg once daily